Semaglutide linked to lower bone fracture risk

Article excerpt

A new study presented at the Endocrine Society's annual meeting found that semaglutide, a diabetes and weight-loss drug, cuts bone fracture risk by 15% in people with type 2 diabetes while delivering greater weight loss than competing anti-obesity medications. The research challenges prior safety concerns about GLP-1 receptor agonists and their effects on bone density. The findings could reshape how doctors weigh the risks and benefits of semaglutide for their diabetic patients, especially those at high fracture risk.